{"id":114320,"date":"2024-04-10T09:39:33","date_gmt":"2024-04-10T04:09:33","guid":{"rendered":"http:\/\/finservwealth.com\/lupin-gets-target-hike-from-nomura-to-rs-1949-on-growth-potential-in-us-products\/"},"modified":"2024-04-10T09:39:33","modified_gmt":"2024-04-10T04:09:33","slug":"lupin-gets-target-hike-from-nomura-to-rs-1949-on-growth-potential-in-us-products","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/lupin-gets-target-hike-from-nomura-to-rs-1949-on-growth-potential-in-us-products\/","title":{"rendered":"Lupin gets target hike from Nomura to Rs 1,949 on growth potential in US products"},"content":{"rendered":"<p> Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.<\/p><div id=\"finse-2763145907\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/lupin-gets-target-hikenomura-to-rs-1949growth-potentialus-products_17520941.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict. Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/lupin-gets-target-hikenomura-to-rs-1949growth-potentialus-products_17520941.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/lupin-gets-target-hikenomura-to-rs-1949growth-potentialus-products_17520941.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict. Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/lupin-gets-target-hikenomura-to-rs-1949growth-potentialus-products_17520941.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-114320","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2024\/200x200\/m\/market_stocks_sensex_Nifty_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/114320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=114320"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/114320\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=114320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=114320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=114320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}